43 patents
Utility
High Surface-Area Lyophilized Compositions Comprising Arsenic For Oral Administration In Patients
5 Oct 23
The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need.
Krishna Vaddi, Kumar Kurumaddali
Filed: 27 Jan 23
Utility
Therapies for Treating Aml and Uses of Rara Agonists, Hypomethylating Agents, and BCL-2 Inhibitors
14 Sep 23
The present disclosure features, inter alia, methods of treating a patient who has been diagnosed with acute myelomonocytic leukemia (the M4 subtype of AML), acute monocytic leukemia (the M5 subtype of AML), or myelodysplastic syndrome (MDS).
Qing Kang-Fortner, Christopher M. Fiore
Filed: 6 Aug 21
Utility
Compounds for the modulation of Myc activity
12 Sep 23
Jason J. Marineau, Peter B. Rahl, Kevin Sprott, Stephane Ciblat, Boubacar Sow, Robin Larouche-Gauthier, Lauren Berstler, Christopher Roberts, Yi Zhang, Francis Beaumier, Luce Lépissier
Filed: 25 Aug 21
Utility
Methods of Treating Cancer In Patients with an Anomalous Kras Gene or Deletions Within Chromosome 9
6 Jul 23
The present invention relates to methods of identifying patients suffering from various types of cancer who are more likely to respond to treatment with a CDK7 inhibitor (e.g., THZ1, THZ2, SY-1365, YKL-5-124, ICEC0942, LY3405105, LDC4297, BS-181, alvocidib, seliciclib, SNS-32 or a pharmaceutically acceptable salt thereof, or a compound of structural Formula (I), (Ia), a species thereof, or a pharmaceutically acceptable salt thereof), either when administered or used alone or in combination with a second therapeutic agent (e.g., another anti-cancer therapy).
John Graeme Hodgson, Liv Helena Johannessen, Nisha Rajagopal, Anthony D'ppolito
Filed: 28 May 21
Utility
Compounds for the Modulation of Myc Activity
11 May 23
Jason J. Marineau, Peter B. Rahl, Kevin Sprott, Stephane Ciblat, Boubacar Sow, Robin Larouche-Gauthier, Lauren Berstler, Christopher Roberts, Yi Zhang, Francis Beaumier, Luce Lépissier
Filed: 13 Jul 22
Utility
Inhibitors of Cyclin Dependent Kinase 7 (CDK7)
2 Mar 23
The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof.
Jason J. Marineau, Robert Zahler, Stephane Ciblat, Dana K. Winter, Anzhelika Kabro, Stephanie Roy, Darby Schmidt, Claudio Chuaqui, Goran Malojcic, Henri Piras, Kenneth Matthew Whitmore, Kate-Lyn Lund, William Sinko, Kevin Sprott
Filed: 8 Feb 22
Utility
Methods of Stratifying Patients for Treatment with Retinoic Acid Receptor-alpha Agonists
9 Feb 23
The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists.
Mei Wei Chen, Cindy Collins, Matthew Lucas Eaton, Matthew G. Guenther, Nan Ke, Jeremy Lopez, Michael Robert McKeown, David A. Orlando
Filed: 22 Jul 22
Utility
Methods of Treating Cancer In Biomarker-identified Patients with Inhibitors of Cyclin-dependent Kinase 7 (CDK7)
5 Jan 23
The present invention relates to methods of identifying patients suffering from various types of cancer who are more likely to respond to treatment with CDK7 inhibitor described herein, or a pharmaceutically acceptable salt thereof, either when administered or used alone or in combination with a second therapeutic agent (e.g., another anti-cancer therapy).
John Graeme Hodgson, Liv Helena Johannessen
Filed: 29 Oct 20
Utility
Compositions and Methods for Treating Sickle Cell Disease
22 Dec 22
The present invention features compositions and methods useful in inhibiting the expression of NFIX within a cell and thereby treating patients suffering from a hemoglobinopathy such as sickle cell disease or β-thalassemia
Jeffrey R. Shearstone
Filed: 6 Nov 20
Utility
Inhibitors of Cyclin Dependent Kinase 7 (CDK7)
29 Sep 22
The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing.
Jason J. Marineau, Claudio Edmundo Chuaqui, Stephane Ciblat, Anzhelika Kabro, Henri Piras, Kenneth Matthew Whitmore, Kate-Lyn Lund
Filed: 4 Mar 22
Utility
Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists
20 Sep 22
The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists.
Mei Wei Chen, Cindy Collins, Matthew Lucas Eaton, Matthew G. Guenther, Nan Ke, Jeremy Lopez, Michael Robert McKeown, David A. Orlando
Filed: 8 May 20
Utility
Inhibitors of cyclin dependent kinase 7 (CDK7)
26 Apr 22
The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing.
Jason J. Marineau, Claudio Edmundo Chuaqui, Stephane Ciblat, Anzhelika Kabro, Henri Piras, Kenneth Matthew Whitmore, Kate-Lyn Lund
Filed: 16 Jan 19
Utility
Compounds for the modulation of MYC activity
15 Mar 22
Jason J. Marineau, Kevin Sprott, Stephane Ciblat, Christopher Roberts, Yi Zhang, Francis Beaumier, Luce Lépissier, Boubacar Sow, Peter B. Rahi, Robin Larouche-Gauthier, Lauren Berstler
Filed: 8 Sep 17
Utility
Compounds for the Modulation of Myc Activity
17 Feb 22
Jason J. Marineau, Peter B Rahl, Kevin Sprott, Stephane Ciblat, Boubacar Sow, Robin Larouche-Gauthier, Lauren Berstler, Christopher Roberts, Yi Zhang, Francis Beaumier, Luce Lépissier
Filed: 25 Aug 21
Utility
Inhibitors of Cyclin Dependent Kinase 7 (CDK7)
6 Jan 22
The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing.
Jason J. Marineau, Claudio Edmundo Chuaqui, Stephane Ciblat, Anzhelika Kabro, Henri Piras, Kenneth Matthew Whitmore, Kate-Lyn Lund, Michael Bradley
Filed: 16 Jan 19
Utility
Methods of Treating Cancer In Biomarker-identified Patients with Non-covalent Inhibitors of Cyclin-dependent Kinase 7 (CDK7)
30 Dec 21
The present invention relates to methods of identifying patients suffering from various types of cancer who are more likely to respond to treatment with a CDK7 inhibitor conforming to structural Formula (I), (Ia), a species thereof, or a specified form thereof (as described herein), either when administered or used alone or in combination with a second therapeutic agent (e.g., another anti-cancer therapy).
John Graeme Hodgson, Liv Helena Johannessen
Filed: 1 Nov 19
Utility
Inhibitors of Cyclin-dependent Kinase 7 (CDK7)
30 Dec 21
The present invention provides various compositions, including compounds of Formula (I) or (Ia), or a species thereof, and pharmaceutically acceptable salts, solvates (e.g., hydrates), stereoisomer, tautomers, isotopic and other specified forms thereof.
Jason J. Marineau, Michael Bradley, Claudio Chuaqui, Stephane Ciblat, Anzhelika Kabro
Filed: 1 Nov 19
Utility
Inhibitors of Cyclin Dependent Kinase 7 (CDK7)
9 Dec 21
The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing.
Jason J. Marineau, Claudio Edmundo Chuaqui, Stephane Ciblat, Anzhelika Kabro, Henri Piras, Kenneth Matthew Whitmore, Kate-Lyn Lund
Filed: 16 Jan 19
Utility
Compounds for the modulation of Myc activity
21 Sep 21
Jason J. Marineau, Peter B. Rahl, Kevin Sprott, Stephane Ciblat, Boubacar Sow, Robin Larouche-Gauthier, Lauren Berstler, Christopher Roberts, Yi Zhang, Francis Beaumier, Luce Lépissier
Filed: 3 Jun 16
Utility
Methods of Stratifying Patients for Treatment with Retinoic Acid Receptor-alpha Agonists
16 Sep 21
Described herein are methods that define cellular populations that are sensitive to RARA agonists and identify patient populations that will benefit from treatment with RARA agonists.
Michael Robert McKeown, Christopher M. Fiore, Matthew Lucas Eaton, Emily Payton Lee, Christian Fritz
Filed: 1 Jun 21